Amphastar Pharmaceuticals, Inc. 10-Q filing
Filed 2026-05-07 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001297184-26-000033
- Form type
- 10-Q
- CIK
- 0001297184
- Primary document
- https://www.sec.gov/Archives/edgar/data/1297184/000129718426000033/amph-20260331x10q.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Amphastar Pharmaceuticals, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $171.2M | - | - |
| Cost Of Revenue | $100.8M | - | - |
| Gross Profit | $70.3M | - | - |
| Operating Income | $13.6M | - | - |
| Net Income | $6.4M | - | - |
| Eps Basic | 0.14 | - | - |
| Eps Diluted | 0.14 | - | - |
| Cash And Equivalents | $170.9M | - | - |
| Total Assets | $1.6B | - | - |
| Total Liabilities | $874.8M | - | - |
| Operating Cash Flow | $47.8M | - | - |
| Capital Expenditures | $9.5M | - | - |